Drug-Related Torsades de Pointes in the Isolated Rabbit Heart
- 1 September 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 32 (3) , 425-434
- https://doi.org/10.1097/00005344-199809000-00013
Abstract
Torsades de pointes is a potentially life-threatening form of polymorphic ventricular tachyarrhythmia typically seen in the presence of repolarization-prolonging agents. We investigated this particular form of tachyarrhythmia in the isolated, perfused rabbit heart. The experimental model was designed to reproduce conditions that are clinically known to be associated with an increased propensity to the development of torsades de pointes. The class III agent clofilium (1 microM) and d,l-sotalol (10 microM), as well as the antibiotic erythromycin (30-150 microM) were infused in the presence of either normal (5.88 mM) or low (1.5 mM) potassium concentration in sinus-driven or atrioventricular (AV)-blocked hearts. Ventricular tachyarrhythmias spontaneously emerged in the clofilium-, d,l-sotalol-, and erythromycin-treated AV-blocked hearts. The episodes showed typical features of torsades de pointes found in humans. They developed within 4-12 min after the onset of infusion, were normally nonsustained, and only rarely degenerated into ventricular fibrillation. Electrical stimulation at cycle lengths <600 ms and perfusion with MgSO4 suppressed arrhythmic activity. In the d,l-sotalol- and erythromycin-treated hearts, torsades de pointes occurred only in the presence of hypokalemia and bradycardia, whereas, in the presence of clofilium, bradycardia alone caused torsades de pointes. Monophasic action-potential recordings demonstrated early afterdepolarizations in endocardial and epicardial recordings. Thus the isolated AV-blocked rabbit heart represents a model for studying drug-related torsades de pointes and its mechanism.Keywords
This publication has 35 references indexed in Scilit:
- Electrophysiologic Features of Torsades de Pointes:Journal of Cardiovascular Electrophysiology, 1997
- Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical ImplicationsJournal of Cardiovascular Electrophysiology, 1995
- Erythromycin-Induced QT Prolongation and Polymorphic Ventricular Tachycardia (Torsades de Pointes): Case Report and ReviewClinical Infectious Diseases, 1994
- Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisationsCardiovascular Research, 1993
- The CASCADE study: Randomized antiarrhythmic drug therapy in survivors of Cardiac Arrest in SeattleThe American Journal of Cardiology, 1993
- Cellular Electrophysiological Effects of the Class III Antiarrhythmic Agents Sematilide and Clofilium on Rabbit Atrial TissuesJournal of Cardiovascular Pharmacology, 1991
- QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the RabbitJournal of Cardiovascular Pharmacology, 1990
- Magnesium Therapy in Ventricular ArrhythmiasPacing and Clinical Electrophysiology, 1990
- Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndromeThe American Journal of Cardiology, 1987
- Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo.Circulation, 1985